Antibody Production
Welcome to QR Labs, where cutting edge science meets excellence in antibody production. Our commitment to quality, ethical practices, and a seasoned scientific team sets us apart in the field.
About Us
QR Labs
Innovation
PROPRIETARY HYBRIDOMA TECHNOLOGY
01.
Our Monoclonal Antibodies
QR Laboratories established a proprietary hybridoma technology and formed the company QR Labs.
The proprietary hybridoma technology offers several advantages in generating monoclonal antibodies.
02.
Proprietary Hybridoma Technology
In the field of innovation in oncology, QR Labs proprietary hybridoma technology, unlike other methods, does not require a priori knowledge and availability of the desired antigen.
03.
TSA
The preservation of the TSA in their native conformational state on the cancer cells.
04.
Efficient Production
The ability to create copious amounts of hybridomas (>1,000) within a short period of time (6-8 weeks), which is far more efficient in comparison to the classic hybridoma technology (a few thousands of antibodies in about 4-6 months).
This capability is crucial since it is expected that the vast majority of the antibodies produced will be targeted against the more abundant and more immunogenic non-cancer antigens.
By creating large hybridoma libraries one increases the probability of detecting those small numbers of poorly immunogenic (“masked”) TSA which normally escape immune surveillance.
05.
Low Cost
In the field of histopathology, where the antigens are known and established, the main advantage of QR Labs’ proprietary technology is the low-cost production of copious amounts of highly specific mAb clones in a very short period of time, within 30 days. These clones exhibit high affinity, avidity, and consistency against the target antigen.
06.
Consistency In Applications
All our antibodies undergo vigorous testing in order to ensure suitability in several applications such as ELISA, immunocytochemistry (ICC), immunohistochemistry (IHC), immunoprecipitation (IP), and Western blot (WB). Additionally, QR Labs’ technology can also be used to generate custom antibodies against various targets, including proteins, carbohydrates, toxins, antibiotics, and allergens.
Animal Contact
Personal Contact
Air Transmission
Contaminate Object
Covid-19 Contagion
How does COVID-19 Spread?
Nec habitasse sociis urna urna dignissim et ac parturient sed mi ultricies porttitor ligula eu elementum arcu leo, cum tellus suspendisse dignissim habitant pellentesque.
- Eu nunc diam sit sed lectus lectus vehicula ut adipiscing quis hendrerit quis arcu gravida
- Non ut vel ornare sit turpis venenatis vitae in lacus, vel in molestie vestibulum cursus dapibus
proprietary hybridoma technology
Our Monoclonal Antibodies Innovation Technology
QR Laboratories established a proprietary hybridoma technology and formed the company QR Labs. The proprietary hybridoma technology offers several advantages in generating monoclonal antibodies:
1. In the field of innovation in oncology, QR Labs proprietary hybridoma technology, unlike other methods, does not require a priori knowledge and availability of the desired antigen. The technology has two major features:
- The preservation of the TSA in their native conformational state on the cancer cells. This is crucial step when one immunizes animals in the
course of hybridoma production. If the conformation of the antigen is not preserved in its native state, the immunized animal will produce antibodies which do not adequately recognize the original, native antigen on the surface of the cancer cell. - The ability to create copious amounts of hybridomas (>1,000) within a short period of time (6-8 weeks), which is far more efficient in comparison to the classic hybridoma technology (a few thousands of antibodies in about 4-6 months). This capability is crucial since it is expected that the vast majority of the antibodies produced will be targeted against the more abundant and more immunogenic non-cancer antigens. By creating large hybridoma libraries one increases the probability of detecting those small numbers of poorly immunogenic (“masked”) TSA which normally escape immune surveillance.
2. In the field of histopathology, where the antigens are known and established, the main advantage of QR Labs’ proprietary technology is the low-cost production of copious amounts of highly specific mAb clones in a very short period of time, within 30 days. These clones exhibit high affinity, avidity, and consistency against the target antigen.
All our antibodies undergo vigorous testing in order to ensure suitability in several applications such as ELISA, immunocytochemistry (ICC), immunohistochemistry (IHC), immunoprecipitation (IP), and Western blot (WB). Additionally, QR Labs’ technology can also be used to generate custom antibodies against various targets, including proteins, carbohydrates, toxins, antibiotics, and allergens.
Stay at home
Nisl, dictum eros lectus fringilla enim quis et malesuada hendrerit arcu, mauris massa penatibus augue sed.
Cover caugh & sneezes
Varius urna ac pulvinar egestas libero tellus, nam amet, mattis lectus ullamcorper nunc elementum id quisque.
Wear a facemask
Sodales magna nisl pellentesque accumsan ut massa sed volutpat tellus tristique pulvinar nisi, eget sed purus.
Clean & disinfectant
Ut aliquet nunc, varius sed leo at pharetra, senectus et semper velit semper nam sed suspendisse.
